Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025. The company will present at TD Cowen's 45th Annual Healthcare Conference on March 3rd at 3:10 p.m. ET, attend investor meetings at the 2025 Leerink Partners Global Healthcare Conference on March 12th, and present at KeyBanc's 5th Annual Healthcare Forum on March 19th at 4:30 p.m. ET.
All presentations will be available via webcast on the company's Investor Relations website, with recordings archived at investors.standardbio.com.
Details
News Market Reaction – LAB
The recorded move for LAB in the trading session of this news was +1.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences:
- TD Cowen’s 45th Annual Healthcare Conference - March 3rd – 5th, 2025
Presenting on Monday, March 3, 2025, at 3:10 p.m. ET - 2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025
Participating in investor meetings on March 12th - KeyBanc’s 5th Annual Healthcare Forum – March 18th & 19th, 2025
Presenting on Wednesday, March 19, 2025, at 4:30 p.m. ET
Presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
ir@standardbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.